At a glance
ClinicalIndex Comparison RecordN/ACompleted· 71 enrolled
Drug / intervention
Mononuclear cell collection.device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
In Brief
An observational study evaluating Mononuclear cell collection. for Leukapheresis. Completed, enrolled 71 participants across 3 sites.
Detailed Summary
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLeukapheresis
CountriesUnited States
CollaboratorsVersiti Blood Health, Key Biologics, LLC, LeukoLab, Yale University
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedJan 17, 2011
Enrollment StartJan 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.5 years ago
Interventions
Mononuclear cell collection.device
Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.